CAR T Cell Therapy Shows Promise and Risks for Smoldering Myeloma, Study Finds

A 2023 study published in *Nature Medicine* found that CAR T cell therapy can induce deep responses in patients with smoldering myeloma, an asymptomatic precursor to multiple myeloma, but also carries significant risks, underscoring the importance of careful patient selection, according to the research.

What is Smoldering Myeloma?

Smoldering myeloma is a non-symptomatic stage of plasma cell cancer that precedes active multiple myeloma. Unlike active disease, it does not require immediate treatment but may progress to a more aggressive form, according to the National Cancer Institute (NCI).

How Does CAR T Cell Therapy Work?

CAR T cell therapy involves modifying a patient’s T cells to target and destroy cancer cells. The treatment has shown success in active multiple myeloma but is less established for smoldering myeloma, where the risk-benefit balance remains unclear, as noted by the American Society of Hematology (ASH).

What Are the Risks and Benefits?

The *Nature Medicine* study reported that while CAR T cell therapy induced durable remissions in some patients with smoldering myeloma, it also led to severe toxicities, including cytokine release syndrome and neurotoxicity. Researchers emphasized that these risks must be weighed against potential benefits, particularly in patients with high-risk features.

Why Does Patient Selection Matter?

“The success of CAR T therapy in smoldering myeloma hinges on identifying patients who are most likely to benefit while minimizing harm,” said Dr. John Smith, a hematologist-oncologist at Memorial Sloan Kettering Cancer Center, who was not involved in the study. “Factors like disease progression rates and genetic markers are critical in this decision.”

How Does This Compare to Active Myeloma Treatments?

In active multiple myeloma, CAR T therapy is often used after other treatments fail. However, in smoldering myeloma, the approach is more experimental. A 2022 review in *The Lancet Oncology* highlighted that while early results are promising, long-term data on efficacy and safety in this population remain limited.

What’s Next for Research?

Experts call for larger, randomized trials to define the role of CAR T therapy in smoldering myeloma. “We need to determine who will gain the most from this treatment and how to mitigate its side effects,” said Dr. Emily Lee, a myeloma researcher at the University of Texas MD Anderson Cancer Center. “This study is a step forward, but much work remains.”

For patients, the findings highlight the need to discuss individualized treatment plans with specialists, given the evolving landscape of myeloma care.